Mirakof: Main Therapeutic Uses and Patient Benefits

The primary role of the medication whose active ingredient is Butamirate Citrate is in the symptomatic management of cough. It is commonly used across domains where short-term symptomatic assistance is needed for a dry (non-productive) cough. This is applicable in clinical settings that involve acute or unstable symptom patterns, such as those associated with conditions presenting with systemic or localized discomfort.

The medication may assist in easing patient distress during difficult episodes. Its use helps address groups of symptoms that interfere with daily comfort. It is also relevant when supportive symptom management is appropriate before or after certain surgical procedures or bronchoscopy.

“It contributes to easing the overall symptom load associated with irritating, dry coughs.”

This supportive relief helps maintain a sense of stability when symptoms are more noticeable and generally assists with maintaining functional stability when symptoms become temporarily overwhelming.

Quick Fact: Relevant for Dry (Non-Productive) Cough Symptoms

Regulatory References

1. Philippines Food and Drug Administration

Who Can and Cannot Use Mirakof?

The eligibility for Mirakof (Butamirate Citrate) is strictly defined by official regulatory documentation, outlining populations for whom use is permitted, restricted, or strictly prohibited.

Conditional Use and Special Populations

The regulatory profile establishes a not recommended status for use during the first trimester of pregnancy and while breastfeeding, though use in later trimesters may be permitted with caution if determined to be absolutely necessary. Furthermore, the official documents state that safety and efficacy data is lacking for patients with impaired renal or hepatic function. Use in these specific conditions requires caution from a prescriber due to the increased risk of accumulation. While generally approved for use in adults and adolescents, the profile notes that use in the geriatric population has not been investigated by the manufacturer.

The official documentation for Butamirate Citrate, the active component of Mirakof, outlines specific restrictions concerning co-administration with other medicinal products and substances. These interaction patterns are primarily categorized by their effect on either drug exposure or physiological outcome.

A formal prohibition exists against the concomitant use of Expectorant Medicines. This is documented as a pharmacodynamic interaction where the antitussive property of Butamirate Citrate may impede the clearance of bronchial secretions, potentially leading to the accumulation of mucus.

Pharmacokinetic interactions govern the use of metabolism-altering substances. Strong Enzyme Inhibitors must not be used together due to the possible risk of increased Butamirate plasma concentration. Additionally, co-administration with other Medicinal Products with a Narrow Therapeutic Index should be restricted, as an altered exposure profile for these co-administered drugs is a documented possibility.

Regarding substances, regulatory labeling specifies that the intake of Alcoholic Beverages should be limited while using this medicine. Furthermore, an important population-specific consideration notes that patients with renal or hepatic impairment may face a greater risk for adverse effects due to potential drug and metabolite accumulation stemming from altered clearance.

Mirakof (Butamirate Citrate) functions as a centrally acting antitussive agent. Its primary mechanism involves the modulation of neuronal activity within the medullary cough center located in the brainstem. The molecule directly interacts with and inhibits the neural pathways responsible for processing afferent signals, thereby elevating the cough threshold. This requires a stronger peripheral stimulus to activate the involuntary cough reflex cascade. Complementary to its central action, Butamirate Citrate exerts distinct effects within the respiratory system. It possesses inherent anti-inflammatory properties, contributing to the reduction of localized tissue irritation and subsequent release of pro-inflammatory mediators. Additionally, the compound demonstrates a moderate bronchodilating effect by influencing the tone of smooth muscle tissue in the airways. These peripheral actions act synergistically with the central nervous system inhibition.

Butamirate Citrate is administered exclusively via the oral route and is available in official dosage forms including syrup, oral drops, and a 50 mg sustained-release (SR) tablet. The specific regimen depends on the patient's age and the preparation used, establishing a standardized protocol for administration.

The standard adult dosing schedule for the sustained-release tablet is 50 mg taken three times daily, with an explicit requirement to maintain at least eight hours between doses and not exceed a maximum of 150 mg per day. The SR tablet must be swallowed whole and not altered to ensure its intended systemic release. The syrup formulation is typically dosed at 15 mL (22.5 mg) up to four times daily. All formulations may be administered with or without food.

Administration protocols are strictly age-dependent. Specialized oral drops are designated for use in infants starting from two months of age, while specific volume adjustments govern the dosing of the syrup for children aged 3 to 12 years. In the event of a missed dose, the official instruction is to continue the regimen with the next scheduled dose; doubling the subsequent dose is prohibited. Use is designated as short-term; a healthcare provider must be consulted if the symptoms persist beyond seven days.

Research evidence / Overview of Studies for Mirakof (Butamirate Citrate)

Evidence for Symptomatic Relief of Irritative (Dry) Cough

Mirakof (butamirate citrate) was studied for use in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations of dry, irritative cough. The research base includes Randomized Controlled Trials (RCTs) and comparative studies, among the designs used to explore short-term symptom changes. Studies primarily examined patient-reported experiences related to physical discomfort and outcomes describing episodic changes in cough frequency and intensity. Findings describe patterns observed in the studies, and researchers reported measurements of cough severity and frequency changed in the observed populations during the short observation window. Research provides insight into short-term changes in acute cough, but studies focusing on episodes where symptoms become more noticeable findings describe group patterns, not personal outcomes.

Research Focus in Procedural Settings (Pre- and Post-Operative)

Butamirate citrate was evaluated in research contexts involving fluctuating or unstable symptoms when cough suppression was necessary before and after certain medical procedures. This specific use is supported by regulatory documentation and older clinical evaluations rather than dedicated contemporary RCTs. Research describes the use in observational settings evaluating daily-life functioning in patients undergoing or recovering from these procedures. Data for certain groups remain insufficient, and there is limited information for long-term outcomes following these interventions.

⏳ Duration of Study and Long-Term Follow-up

Butamirate citrate was studied for acute or short-term symptomatic use. The follow-up durations were limited, typically spanning only a few days (e.g., up to one week) in the main clinical trials. This means the research provides insight into short-term changes, but there is limited information for long-term outcomes. Long-term outcomes are not well characterized because studies exploring extended or continuous use for chronic cough are not well-represented in the current evidence landscape.

Key Research Gaps and Areas of Uncertainty

The research highlights what is known, but also what is still uncertain. Evidence quality varies across studies, with some foundational trials being older. Sample sizes were modest in some key investigations, which means findings describe group patterns, not personal outcomes with high certainty. Comparative evidence is lacking or inconclusive in fully establishing how butamirate citrate compares to every alternative antitussive in every scenario, and research is ongoing to fill these data gaps.

Key Studies & References

1. Philippines Food and Drug Administration Drug Registration Process: Mirakof (Butamirate Citrate) Patient Information Leaflet

Common questions about Mirakof (FAQ)

Q: Is Mirakof used for both dry cough and cough with mucus?

Mirakof is classified as an antitussive and is officially indicated for the symptomatic treatment of non-productive (dry) cough. Official product information contains a prohibition against using this medicine at the same time as expectorants, which are medicines intended to help clear mucus.

Q: Is Mirakof a scheduled or controlled substance?

Official pharmacological descriptions state that Mirakof (Butamirate Citrate) is a non-narcotic substance. Regulatory documents clarify that it is not chemically or pharmacologically related to the class of opioid alkaloids.

Q: How long can the effect of one dose of Mirakof be expected to last?

The dosing protocol for the sustained-release tablet requires a minimum of eight hours between doses, which suggests the intended duration of effect. Official pharmacokinetic data indicates that the apparent elimination half-life of the principal active metabolite is approximately six hours.

Q: What should be expected if Mirakof does not seem to be working?

Mirakof is designated for short-term symptomatic use. Official administration guidance states that if the cough symptoms persist beyond seven days, or if they are accompanied by fever or breathing difficulties, official guidance notes that consultation with a healthcare provider is necessary.

Q: Is Mirakof ever used to help with sleep due to cough?

The only therapeutic purpose for this medicine is symptomatic cough relief. While drowsiness (somnolence) is listed in regulatory documents as a rare potential side effect, it is not listed as a therapeutic indication for sleep.

Q: What is the research evidence for Mirakof's use in children?

Official product labels include specific age restrictions and contraindications for young children. This is due to a documented lack of sufficient safety and efficacy data in that specific age group. Use in infants and children requires strict adherence to the age-dependent administration protocols established by regulatory authorities.

Q: What are the concerns about using Mirakof during the first trimester of pregnancy?

Official regulatory documentation states that the medicine is subject to an official restriction that advises against its use during the first trimester of pregnancy. This restriction is noted because no studies have been conducted to determine the safety of the drug in pregnant women during this period.

Q: Does Mirakof contain any sugar, for people with diabetes?

Some formulations contain the excipient sorbitol, which is relevant for patients with specific sugar intolerances. Because of this, patients with hereditary fructose intolerance are subject to a formal contraindication against using certain forms. For patients with an intolerance to some sugars, official labeling states consultation with a healthcare professional is necessary regarding the specific formulation.

Q: Is Mirakof known to cause addiction or dependency?

Official pharmacological information states that Mirakof is a non-narcotic substance. It is documented that this medicine does not produce undesirable effects such as addiction or dependency.

Q: Can Mirakof be used for a cough caused by allergies?

Regulatory documents state that the medicine is indicated for the symptomatic treatment of dry cough of various origins. It is not specifically labeled for allergic cough, which may require a different class of medicine to address the underlying cause.

Q: How quickly does Mirakof usually start working?

Official pharmacokinetic information indicates that the onset of action is relatively rapid. Relief from cough symptoms is often reported as beginning within 30 minutes to an hour after administration.

Q: Can Mirakof cause heart palpitations or changes in blood pressure?

Low blood pressure, which is medically referred to as hypotension, is listed as a potential symptom in regulatory documents. However, this is described only in the context of accidental overdose and is not listed as a rare side effect when the medicine is taken as directed.

Q: Are there any known food or supplement interactions with Mirakof?

The official method of administration states that the product may be taken with or without food. No specific interactions with common food products or supplements are documented in the core regulatory label.

Q: Can Mirakof be taken safely with prescription sleep aids?

Official product information advises caution regarding co-administration with other medicinal products. This warning applies particularly to medications that may cause central nervous system (CNS) depression or general drowsiness.

Q: What is the risk of overdose symptoms with Mirakof?

Regulatory documents describe the potential symptoms of an accidental overdose with Butamirate Citrate. These can include drowsiness, nausea, vomiting, diarrhea, dizziness, and low blood pressure (hypotension).

How to Store and Dispose of Mirakof

Official regulatory information outlines specific requirements for storing and disposing of Mirakof to ensure its stability and safety. The unopened product must be stored in a refrigerator, strictly maintained between 2 C and 8 C (36 F and 46 F), and must be protected from freezing at all times.

To safeguard its stability, the medication must be kept in its original carton to protect it from light until the time of use. After the vial has been reconstituted and diluted, the prepared infusion solution has a limited stability period and must be used within 48 hours from the initial puncture time.

Keep the product out of the reach of children. Unused or expired Mirakof and related drug materials must be disposed of properly. Do not flush the medication down the toilet; instead, follow local regulations for the disposal of pharmaceutical waste, such as a drug take-back program.